AIFA insists it followed rules on Mifegyne approval
This article was originally published in Scrip
Executive Summary
AIFA, the Italian medicines agency, continues to defend itself against criticism from strong opponents of abortion following its approval of a marketing authorisation for Exelgyn's abortifacient Mifegyne (mifepristone), known previously as RU-486.